# High accuracy in detecting HER2‐low status in FNA of primary and metastatic breast cancer

**Authors:** Giuseppe D’Abbronzo, Stefano Lucà, Immacolata Cozzolino, Marina Accardo, Carminia Della Corte, Francesco Iovino, Simona Parisi, Ilaria Tedesco, Francesco Ingallinella, Francesca Grasso, Renato Franco, Marco Montella

PMC · DOI: 10.1002/cncy.70085 · Cancer Cytopathology · 2026-02-27

## TL;DR

Fine-needle aspiration cytology can reliably detect HER2-low breast cancer when biopsies are not possible.

## Contribution

FNAC-derived cell blocks show high specificity and positive predictive value for HER2-low detection.

## Key findings

- ICC on FNAC-derived CBs showed high specificity (85.7–92.9%) for HER2-low tumors.
- Concordance between cytological and histological HER2-low assessment exceeded 90%.
- FNAC-derived CBs are a reliable alternative when histological samples are unavailable.

## Abstract

HER2‐positive invasive breast carcinomas (IBCs) account for 15% of breast cancers and are driven by ERBB2 gene amplification. Although historically associated with aggressive behavior, HER2‐targeted therapies have significantly improved outcomes. HER2 status is routinely assessed by immunohistochemistry (IHC) and in situ hybridization (ISH). Recently, tumors with low HER2 expression (IHC 1+ or 2+ without amplification), previously classified as HER2‐negative, have emerged as a clinically relevant subgroup. Fine‐needle aspiration cytology (FNAC) is a minimally invasive alternative to core needle biopsy, particularly useful in inoperable or metastatic settings. FNAC‐derived cell blocks (CBs) allow immunocytochemical (ICC) evaluation of biomarkers.

This retrospective study included 46 FNAC‐derived CBs from breast cancers (34 primary tumors and 12 metastases) collected at Vanvitelli University Hospital. ICC evaluation of HER2, estrogen receptor (ER), and progesterone receptor (PR) was independently performed by two expert pathologists and compared with corresponding histological assessments. Diagnostic performance was evaluated using sensitivity, specificity, predictive values, concordance rates, and receiver operating characteristic (ROC) curve analysis.

ICC on FNAC‐derived CBs showed good diagnostic performance for HER2‐low tumors. Sensitivity ranged from 56.3% to 59.4%, whereas specificity was high (85.7%–92.9%). Positive predictive values reached 90.0%–95.0%, whereas negative predictive values were lower (46.2%–50.0%). Concordance between cytological and histological HER2‐low assessment exceeded 90%, with ROC area under the curve values of 0.71–0.76. ER showed excellent concordance, whereas PR demonstrated moderate agreement.

FNAC‐derived CBs are a reliable tool for identifying HER2‐low breast carcinomas when histological samples are unavailable or limited, emphasizing the need for standardized evaluation criteria.

This study demonstrates that fine‐needle aspiration cytology with cell block preparation provides high specificity and positive predictive value for the detection of HER2‐low breast carcinomas. Despite moderate sensitivity, cytological assessment represents a valuable diagnostic alternative when core biopsy is unavailable or impractical.

## Linked entities

- **Genes:** ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064], EREG (epiregulin) [NCBI Gene 2069], PGR (progesterone receptor) [NCBI Gene 5241]
- **Proteins:** ERBB2 (erb-b2 receptor tyrosine kinase 2)
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}
- **Diseases:** ductal carcinoma in situ (MESH:D002285), cancer (MESH:D009369), CAP (OMIM:115650), invasive papillary carcinoma (MESH:D002291), invasive carcinoma (MESH:D009361), IBC-NST (MESH:D001943), -negative (MESH:D064726), mucinous carcinoma (MESH:D002288), invasive lobular carcinoma (MESH:D018275), bone metastases (MESH:D009362), endometrial and breast carcinoma (MESH:C537262)
- **Chemicals:** paraffin (MESH:D010232), alcohol (MESH:D000438), DAB (MESH:C000469), formalin (MESH:D005557), trastuzumab deruxtecan (MESH:C000614160), CB (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12947610/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12947610/full.md

## References

32 references — full list in the complete paper: https://tomesphere.com/paper/PMC12947610/full.md

---
Source: https://tomesphere.com/paper/PMC12947610